Received May 14, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
late dose/patient who received his first dose of SHINGRIX in October 2018 and his second dose in February 2026.; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 77-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received in OCT-2018). In FEB-2026, the patient received the 2nd dose of Shingrix. In FEB-2026, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: late dose/patient who received his first dose of SHINGRIX in October 2018 and his second dose in February 2026.). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date:01-MAY-2026 The batch number was not provided and a request for this information has been made